Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Urothelial Carcinoma Patients Have High Risk of Chemo-Related VTEs

December 9, 2015
By Dave Levitan
Article

Patients with metastatic or unresectable urothelial carcinoma who are treated with either carboplatin or cisplatin have high rates of vascular thromboembolic events.

Patients with metastatic or unresectable urothelial carcinoma who are treated with either carboplatin or cisplatin have high rates of vascular thromboembolic events (VTEs), according to results of a new study.

Previous research has shown that cancer and cancer therapy both may raise the risk of VTEs including deep vein thrombosis, pulmonary embolus, and others. This could be due to several mechanisms, including activation of coagulation cascades and a magnification of effects by chemotherapeutics. Bladder cancer is among several other malignancies believed to carry the highest risk for such events, and previous reports suggested higher rates of VTEs with cisplatin-based therapies than with carboplatin-based regimens.

The new study, led by Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center in New York, compared rates of VTEs in urothelial carcinoma patients treated with gemcitabine and either cisplatin or carboplatin, or in combination with carboplatin and bevacizumab. The results were published online ahead of print in Cancer.

The study included a total of 198 patients: 51 received gemcitabine, carboplatin, and bevacizumab; 92 patients received gemcitabine and carboplatin; and 55 patients received gemcitabine and cisplatin. There were significant differences between the groups with regard to age, prior cystectomy, tumor location near pelvic vessels, Khorana risk group, and receipt of antiplatelet therapy.

A total of 13 of 51 of the patients who received gemcitabine, carboplatin, and bevacizumab experienced a VTE (25.5%), compared with 22 of 92 gemcitabine/carboplatin patients (23.9%), and 8 of 55 gemcitabine/cisplatin patients (14.5%). This was not significantly different between the chemotherapy groups (P = .300). Most VTEs in each group were venous, and the type of VTE did not significantly differ between groups (P = 0.111).

The authors also conducted a regression analysis to search for factors associated with increased VTE risk. The only such factor found was prior cystectomy, which carried an odds ratio for VTE of 2.22 (95% confidence interval, 1.01–4.86; P = .047).

The authors wrote that these rates of VTE mirror other reports involving cisplatin, but the 24% in carboplatin-treated patients was particularly high. The high rates of this complication raise questions of whether these patients should be monitored or treated differently, but the authors wrote that prophylaxis for all patients may be problematic given various factors including ongoing hematuria that could worsen with anticoagulation. A further study now ongoing aims to identify high-risk patients that may benefit from such prophylactic therapy.

“These observations add to our understanding of the adverse effects associated with platinum-based therapy for patients with advanced [urothelial carcinoma], although the causes and impact of chemotherapy-associated VTEs warrant further investigation,” the authors concluded.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

Russ Conroy
July 1st 2025
Article

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
June 18th 2025
Article

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.


NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.


Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Gina Mauro
June 11th 2025
Article

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.


A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Related Content

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

Russ Conroy
July 1st 2025
Article

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
June 18th 2025
Article

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.


NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.


Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Gina Mauro
June 11th 2025
Article

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.


A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.